非酒精性脂肪性肝炎大鼠模型中肝纤维化及治疗反应的先进MRI研究
研究在大鼠非酒精性脂肪性肝炎模型中前瞻性比较I型胶原靶向探针EP-3533、醛赖氨酸靶向纤维化探针Gd-Hyd、MR弹性成像和原生T1对肝纤维化的分期能力及治疗反应评估价值。以数字病理胶原面积比例为参考,EP-3533鉴别纤维化的AUC最高(0.95),Gd-Hyd判别治疗反应准确率最高(24/26,92%)。
要点
- EP-3533鉴别纤维化(CPA>4.8%)的AUC为0.95,优于原生T1、Gd-Hyd和MR弹性成像。
- Gd-Hyd判别晚期纤维化(CPA>10.3%)的AUC为0.96,高于EP-3533、MR弹性成像和原生T1。
- Gd-Hyd识别治疗反应者与非反应者的准确率最高(24/26,92%)。
核心结论
- 胶原靶向分子MRI对早期纤维化检出最准确,而纤维化生成探针Gd-Hyd对治疗反应的检测最准确。
研究设计与样本
- 前瞻性动物研究,2018年6月至11月对六组雄性Wistar大鼠行MRI,每组样本量分别为12、12、8、8、12、14只。
- 组别包括年龄匹配和体重匹配的标准饲料对照组、6周或9周CDAHFD饮食组、6周CDAHFD后恢复标准饲料3周组、9周CDAHFD并从第6周起每日elafibranor治疗组。
- 以定量数字病理胶原面积比例(CPA)为参考标准,用ROC曲线下面积(AUC)评估各影像指标分期纤维化的能力。
诊断标准与关键数值
- 鉴别纤维化(CPA>4.8%)与非纤维化(CPA≤4.8%)的AUC:EP-3533为0.95(95%CI:0.91,1.00),原生T1为0.90(95%CI:0.83,0.98),Gd-Hyd为0.84(95%CI:0.74,0.95),MR弹性成像为0.65(95%CI:0.51,0.79)。
- 判别晚期纤维化(CPA>10.3%)的AUC:EP-3533为0.86(95%CI:0.76,0.97),Gd-Hyd为0.96(95%CI:0.90,1.01),MR弹性成像为0.84(95%CI:0.70,0.98),原生T1为0.74(95%CI:0.63,0.86)。
- 识别治疗组中反应者与非反应者的准确率:Gd-Hyd为24/26(92%,95%CI:75%,99%),MR弹性成像为23/26(88%,95%CI:70%,98%),EP-3533为20/26(77%,95%CI:56%,91%),原生T1为14/26(54%,95%CI:33%,73%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Liver biopsy is the reference standard to diagnose nonalcoholic steatohepatitis (NASH) but is invasive with potential complications. Purpose To evaluate molecular MRI with type 1 collagen-specific probe EP-3533 and allysine-targeted fibrogenesis probe Gd-Hyd, MR elastography, and native T1 to characterize fibrosis and to assess treatment response in a rat model of NASH. Materials and Methods MRI was performed prospectively (June-November 2018) in six groups of male Wistar rats (a) age- and (b) weight-matched animals received standard chow (n = 12 per group); (c) received choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 6 weeks or (d) 9 weeks (n = 8 per group); (e) were fed 6 weeks of CDAHFD and switched to standard chow for 3 weeks (n = 12); (f) were fed CDAHFD for 9 weeks with daily treatment of elafibranor beginning at week 6 (n = 14). Differences in imaging measurements and tissue analyses among groups were tested with one-way analysis of variance. The ability of each imaging measurement to stage fibrosis was quantified by using area under the receiver operating characteristic curve (AUC) with quantitative digital pathology (collagen proportionate area [CPA]) as reference standard. Optimal cutoff values for distinguishing advanced fibrosis were used to assess treatment response. Results AUC for distinguishing fibrotic (CPA >4.8%) from nonfibrotic (CPA ≤4.8%) livers was 0.95 (95% confidence interval [CI]: 0.91, 1.00) for EP-3533, followed by native T1, Gd-Hyd, and MR elastography with AUCs of 0.90 (95% CI: 0.83, 0.98), 0.84 (95% CI: 0.74, 0.95), and 0.65 (95% CI: 0.51, 0.79), respectively. AUCs for discriminating advanced fibrosis (CPA >10.3%) were 0.86 (95% CI: 0.76, 0.97), 0.96 (95% CI: 0.90, 1.01), 0.84 (95% CI: 0.70, 0.98), and 0.74 (95% CI: 0.63, 0.86) for EP-3533, Gd-Hyd, MR elastography, and native T1, respectively. Gd-Hyd MRI had the highest accuracy (24 of 26, 92%; 95% CI: 75%, 99%) in identifying responders and nonresponders in the treated groups compared with MR elastography (23 of 26, 88%; 95% CI: 70%, 98%), EP-3533 (20 of 26, 77%; 95% CI: 56%, 91%), and native T1 (14 of 26, 54%; 95% CI: 33%, 73%). Conclusion Collagen-targeted molecular MRI most accurately detected early onset of fibrosis, whereas the fibrogenesis probe Gd-Hyd proved most accurate for detecting treatment response. © RSNA, 2020 Online supplemental material is available for this article.
引用
- Zhou IY, Clavijo Jordan V, Rotile NJ, et al. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology. 2020. PMID: 32343209. doi:10.1148/radiol.2020192118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。